Home › Compare › CYTO vs ORCC

CYTO vs ORCC: Dividend Comparison 2026

CYTO yields 666.67% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTO wins by $608115.64M in total portfolio value
10 years
CYTO
CYTO
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full CYTO calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CYTO vs ORCC

📍 CYTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTOORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTO + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYTO pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTO
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CYTO beats the other by $399,126,865,992.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTO + ORCC for your $10,000?

CYTO: 50%ORCC: 50%
100% ORCC50/50100% CYTO
Portfolio after 10yr
$304057.84M
Annual income
$234,780,509,408.64/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CYTO
No analyst data
Altman Z
-1.2
Piotroski
5/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTO buys
0
ORCC buys
0
No recent congressional trades found for CYTO or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTOORCC
Forward yield666.67% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$608115.66M ✓$21.4K
Annual income after 10y$469,561,018,816.25 ✓$1.04
Total dividends collected$596792.85M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CYTO vs ORCC ($10,000, DRIP)

YearCYTO PortfolioCYTO Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$77,367$66,666.67$11,190$489.61+$66.2K → CYTO
2$564,818$482,035.31$12,229$256.01+$552.6K → CYTO
3$3,893,246$3,288,890.67$13,216$130.74+$3.88M → CYTO
4$25,352,760$21,186,987.16$14,207$66.02+$25.34M → CYTO
5$156,070,781$128,943,327.59$15,234$33.17+$156.06M → CYTO
6$908,837,800$741,842,064.29$16,317$16.62+$908.82M → CYTO
7$5,009,769,782$4,037,313,336.56$17,468$8.32+$5009.75M → CYTO
8$26,159,339,258$20,798,885,591.56$18,695$4.16+$26159.32M → CYTO
9$129,490,317,125$101,499,824,118.87$20,006$2.08+$129490.30M → CYTO
10$608,115,658,140$469,561,018,816.25$21,407$1.04+$608115.64M → CYTO

CYTO vs ORCC: Complete Analysis 2026

CYTO — Stock

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Full CYTO Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CYTO vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTO vs SCHDCYTO vs JEPICYTO vs OCYTO vs KOCYTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.